urea has been researched along with Tachycardia, Supraventricular in 13 studies
pseudourea: clinical use; structure
isourea : A carboximidic acid that is the imidic acid tautomer of urea, H2NC(=NH)OH, and its hydrocarbyl derivatives.
Tachycardia, Supraventricular: A generic expression for any tachycardia that originates above the BUNDLE OF HIS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The purpose of this study was to find a safe dosing regimen for landiolol, an ultra-short-acting β-adrenergic blocking agent, to rapidly control supraventricular tachyarrhythmias (SVTs) in patients with heart failure (HF)." | 7.80 | Novel use of the ultra-short-acting intravenous β1-selective blocker landiolol for supraventricular tachyarrhythmias in patients with congestive heart failure. ( Adachi, T; Aonuma, K; Baba, M; Hasegawa, T; Hiraya, D; Hoshi, T; Kuroki, K; Sato, A, 2014) |
| "The response to continuous intravenous infusion of landiolol was evaluated in 25 patients who developed post-operative atrial fibrillation or atrial flutter after major pulmonary resection." | 7.78 | Effect of landiolol hydrochloride, an ultra-short-acting beta 1-selective blocker, on supraventricular tachycardia, atrial fibrillation and flutter after pulmonary resection. ( Ibe, T; Kamiyoshihara, M; Kawashima, O; Nagashima, T; Nakano, T; Shimizu, K; Takeyoshi, I, 2012) |
| "Landiolol is an ultra-short-acting β1-selective blocker whose effect on tachyarrhythmia after TCPC is unclear." | 5.43 | Effects of landiolol on refractory tachyarrhythmia after total cavopulmonary connection: a retrospective, observational, cohort study. ( Fujita, Y; Miyake, K; Miyazu, M; Sento, Y; Sobue, K; Tomita, M; Yoshimura, S; Yoshizawa, S, 2016) |
| " In paroxysmal atrial fibrillation, landiolol hydrochloride reduced the heart rate from 111 +/- 20 to 90 +/- 10/min." | 5.09 | Pharmacokinetics of landiolol hydrochloride, a new ultra-short-acting beta-blocker, in patients with cardiac arrhythmias. ( Atarashi, H; Endoh, Y; Hayakawa, H; Ino, T; Kuruma, A; Saitoh, H; Yashima, M, 2000) |
| "The purpose of this study was to find a safe dosing regimen for landiolol, an ultra-short-acting β-adrenergic blocking agent, to rapidly control supraventricular tachyarrhythmias (SVTs) in patients with heart failure (HF)." | 3.80 | Novel use of the ultra-short-acting intravenous β1-selective blocker landiolol for supraventricular tachyarrhythmias in patients with congestive heart failure. ( Adachi, T; Aonuma, K; Baba, M; Hasegawa, T; Hiraya, D; Hoshi, T; Kuroki, K; Sato, A, 2014) |
| "The response to continuous intravenous infusion of landiolol was evaluated in 25 patients who developed post-operative atrial fibrillation or atrial flutter after major pulmonary resection." | 3.78 | Effect of landiolol hydrochloride, an ultra-short-acting beta 1-selective blocker, on supraventricular tachycardia, atrial fibrillation and flutter after pulmonary resection. ( Ibe, T; Kamiyoshihara, M; Kawashima, O; Nagashima, T; Nakano, T; Shimizu, K; Takeyoshi, I, 2012) |
| " The safety endpoint was the incidence of adverse events in each of the three groups." | 2.78 | The effectiveness and safety of landiolol hydrochloride, an ultra-short-acting β1-blocker, in postoperative patients with supraventricular tachyarrhythmias: a multicenter, randomized, double-blind, placebo-controlled study. ( Kikawa, S; Taenaka, N, 2013) |
| "Septic shock is a life-threatening condition that occurs when the blood pressure drops to a low level after an infection." | 1.46 | Landiolol is effective for the treatment of tachycardia-induced cardiogenic shock in patients during septic shock therapy. ( Arita, Y; Hasegawa, S; Segawa, T; Yamamoto, S, 2017) |
| "Landiolol is an ultra-short-acting β1-selective blocker whose effect on tachyarrhythmia after TCPC is unclear." | 1.43 | Effects of landiolol on refractory tachyarrhythmia after total cavopulmonary connection: a retrospective, observational, cohort study. ( Fujita, Y; Miyake, K; Miyazu, M; Sento, Y; Sobue, K; Tomita, M; Yoshimura, S; Yoshizawa, S, 2016) |
| "Landiolol hydrochloride is a newly developed ultra short-acting selective beta1-blocker with a half-life of approximately 4 minutes." | 1.35 | [Clinical evaluation of landiolol hydrochloride, an ultra short-acting beta-blocker]. ( Kasuya, S; Kikuchi, C; Saito, N; Tanaka, S, 2008) |
| "Digoxin was prescribed according to the nomogram with the addition of a dosage correction based on the plasma digoxin level on Day 3." | 1.27 | A simple aid to digoxin prescribing. ( Johnston, GD; McDevitt, DG; Taggart, AJ, 1987) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (7.69) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (23.08) | 29.6817 |
| 2010's | 9 (69.23) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Arita, Y | 1 |
| Segawa, T | 1 |
| Yamamoto, S | 1 |
| Hasegawa, S | 1 |
| Syed, YY | 1 |
| Adachi, T | 1 |
| Sato, A | 1 |
| Baba, M | 1 |
| Hiraya, D | 1 |
| Hasegawa, T | 1 |
| Kuroki, K | 1 |
| Hoshi, T | 1 |
| Aonuma, K | 1 |
| Taenaka, N | 1 |
| Kikawa, S | 1 |
| Xiao, J | 1 |
| He, P | 1 |
| Zou, Q | 1 |
| Zhao, Y | 1 |
| Xue, Z | 1 |
| Deng, X | 1 |
| Li, S | 1 |
| Guo, Q | 1 |
| Tao, G | 1 |
| Yang, T | 1 |
| Lang, Z | 1 |
| He, J | 1 |
| Wang, X | 1 |
| Miyake, K | 1 |
| Fujita, Y | 1 |
| Yoshizawa, S | 1 |
| Tomita, M | 1 |
| Miyazu, M | 1 |
| Sento, Y | 1 |
| Yoshimura, S | 1 |
| Sobue, K | 2 |
| Hakone, M | 1 |
| Yamada, T | 1 |
| Motoyasu, A | 1 |
| Kasuya, Y | 1 |
| Yorozu, T | 1 |
| Tanaka, S | 1 |
| Kikuchi, C | 1 |
| Saito, N | 1 |
| Kasuya, S | 1 |
| Nakano, T | 1 |
| Shimizu, K | 1 |
| Kawashima, O | 1 |
| Kamiyoshihara, M | 1 |
| Nagashima, T | 1 |
| Ibe, T | 1 |
| Takeyoshi, I | 1 |
| Morisaki, A | 1 |
| Hosono, M | 1 |
| Sasaki, Y | 1 |
| Hirai, H | 1 |
| Sakaguchi, M | 1 |
| Nakahira, A | 1 |
| Seo, H | 1 |
| Suehiro, S | 1 |
| Ito, H | 1 |
| So, M | 1 |
| Hirate, H | 1 |
| Sugiura, T | 1 |
| Azami, T | 1 |
| Sasano, H | 1 |
| Katsuya, H | 1 |
| Atarashi, H | 1 |
| Kuruma, A | 1 |
| Yashima, M | 1 |
| Saitoh, H | 1 |
| Ino, T | 1 |
| Endoh, Y | 1 |
| Hayakawa, H | 1 |
| Taggart, AJ | 1 |
| McDevitt, DG | 1 |
| Johnston, GD | 1 |
1 review available for urea and Tachycardia, Supraventricular
| Article | Year |
|---|---|
Landiolol: A Review in Tachyarrhythmias.
Topics: Administration, Intravenous; Adrenergic beta-1 Receptor Antagonists; Atrial Fibrillation; Dose-Respo | 2018 |
3 trials available for urea and Tachycardia, Supraventricular
| Article | Year |
|---|---|
The effectiveness and safety of landiolol hydrochloride, an ultra-short-acting β1-blocker, in postoperative patients with supraventricular tachyarrhythmias: a multicenter, randomized, double-blind, placebo-controlled study.
Topics: Adrenergic beta-Antagonists; Aged; Dose-Response Relationship, Drug; Double-Blind Method; Female; He | 2013 |
Landiolol in the treatment of the intraoperative supraventricular tachycardia: a multicenter, randomized, double-blind, placebo-controlled study.
Topics: Adrenergic beta-1 Receptor Antagonists; Adult; Aged; Anti-Arrhythmia Agents; Blood Pressure; Double- | 2015 |
Pharmacokinetics of landiolol hydrochloride, a new ultra-short-acting beta-blocker, in patients with cardiac arrhythmias.
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; D | 2000 |
9 other studies available for urea and Tachycardia, Supraventricular
| Article | Year |
|---|---|
Landiolol is effective for the treatment of tachycardia-induced cardiogenic shock in patients during septic shock therapy.
Topics: Aged; Anti-Arrhythmia Agents; Diagnosis, Differential; Electrocardiography; Female; Humans; Morpholi | 2017 |
Novel use of the ultra-short-acting intravenous β1-selective blocker landiolol for supraventricular tachyarrhythmias in patients with congestive heart failure.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Atrial Fibrillation; Blood Pressure; Drug Administrati | 2014 |
Effects of landiolol on refractory tachyarrhythmia after total cavopulmonary connection: a retrospective, observational, cohort study.
Topics: Blood Pressure; Child; Child, Preschool; Cohort Studies; Female; Fontan Procedure; Heart Rate; Human | 2016 |
[Anesthetic Management of a Patient who Developed Intraoperative Paroxysmal Supraventricular Tachycardia with Pulseless Electric Activity].
Topics: Adrenergic beta-Antagonists; Aged; Anesthetics; Anti-Arrhythmia Agents; Electrocardiography; Female; | 2016 |
[Clinical evaluation of landiolol hydrochloride, an ultra short-acting beta-blocker].
Topics: Adrenergic beta-Antagonists; Aged; Anti-Arrhythmia Agents; Double-Blind Method; Female; Humans; Male | 2008 |
Effect of landiolol hydrochloride, an ultra-short-acting beta 1-selective blocker, on supraventricular tachycardia, atrial fibrillation and flutter after pulmonary resection.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Aged, 80 and over; Atrial Fibrillation; Atrial Flutter | 2012 |
Very-low-dose continuous drip infusion of landiolol hydrochloride for postoperative atrial tachyarrhythmia in patients with poor left ventricular function.
Topics: Aged; Anti-Arrhythmia Agents; Coronary Artery Bypass; Female; Heart Diseases; Heart Rate; Heart Valv | 2012 |
Use of landiolol in the perioperative management of supraventricular tachycardia.
Topics: Anti-Arrhythmia Agents; Cardiac Surgical Procedures; Cardiopulmonary Bypass; Cardiotonic Agents; Dop | 2006 |
A simple aid to digoxin prescribing.
Topics: Adult; Aged; Aged, 80 and over; Algorithms; Digoxin; Female; Heart Failure; Humans; Male; Middle Age | 1987 |